RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ligand Pharmaceuticals Stock

Ligand Pharmaceuticals P/S 2024

Ligand Pharmaceuticals P/S

9.96

Ticker

LGND

ISIN

US53220K5048

WKN

A1C9RN

As of Aug 27, 2024, Ligand Pharmaceuticals's P/S ratio stood at 9.96, a 3.43% change from the 9.63 P/S ratio recorded in the previous year.

The Ligand Pharmaceuticals P/S history

Ligand Pharmaceuticals Aktienanalyse

What does Ligand Pharmaceuticals do?

Ligand Pharmaceuticals Inc is an American company that has been operating in the biotechnology industry for over 30 years. It was founded in 1987 in San Diego, California and has since built an impressive track record. The business model of Ligand Pharmaceuticals Inc is based on the development and commercialization of innovative drugs and technologies for the pharmaceutical and biotechnology industry. The company is a leading provider of resources for drug discovery and development, including ligand design, synthesis and analysis, tools for drug screening, and technologies for therapy optimization. Ligand Pharmaceuticals Inc is divided into several business segments that focus on different industries and categories of medication. These include oncology, immunology, neurology, metabolic diseases, and rare diseases. One of the key areas of Ligand Pharmaceuticals Inc is oncology, which focuses on the development of cancer drugs. The company currently has several innovative drugs in the pipeline targeting various types of cancer and showing promising results in clinical trials. Another important area of Ligand Pharmaceuticals Inc is immunology, which focuses on the development of drugs for autoimmune diseases. The company has some promising partnerships in this field, including one with Bristol Myers Squibb for the joint development of antibodies against the CTLA-4 receptor. In addition to drug development, Ligand Pharmaceuticals Inc also offers various technologies and tools for drug screening and therapy optimization. These include platforms for antibody and small molecule discovery, as well as technologies for antibody manufacturing and genome editing. Another important aspect of Ligand Pharmaceuticals Inc's business model is its partnership with other pharmaceutical companies. The company heavily relies on collaboration and currently has several strategic partnerships with some of the world's largest pharmaceutical companies. These partnerships allow Ligand to provide its partners with access to its technology and drug candidates, thereby expanding its portfolio. Over the years, Ligand Pharmaceuticals Inc has brought many successful products and technologies to the market. Some of the most well-known and successful products include Kyprolis, a treatment for multiple myeloma, and Promacta, a medication for immune thrombocytopenia. Overall, Ligand Pharmaceuticals Inc has built an impressive track record and is now considered one of the leading providers of resources for drug discovery and development. The company continues to prioritize collaboration and innovation and will undoubtedly bring many more innovative products and technologies to the market in the future. Ligand Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Ligand Pharmaceuticals's P/S Ratio

Ligand Pharmaceuticals's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Ligand Pharmaceuticals's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Ligand Pharmaceuticals's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Ligand Pharmaceuticals’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Ligand Pharmaceuticals stock

What is the price-to-earnings ratio of Ligand Pharmaceuticals?

The price-earnings ratio of Ligand Pharmaceuticals is currently 9.96.

How has the price-earnings ratio of Ligand Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Ligand Pharmaceuticals has increased by 3.43% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Ligand Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Ligand Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Ligand Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Ligand Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Ligand Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Ligand Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Ligand Pharmaceuticals?

Some factors that influence the price-earnings ratio of Ligand Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Ligand Pharmaceuticals pay?

Over the past 12 months, Ligand Pharmaceuticals paid a dividend of 15 USD . This corresponds to a dividend yield of about 14.26 %. For the coming 12 months, Ligand Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Ligand Pharmaceuticals?

The current dividend yield of Ligand Pharmaceuticals is 14.26 %.

When does Ligand Pharmaceuticals pay dividends?

Ligand Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ligand Pharmaceuticals?

Ligand Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Ligand Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ligand Pharmaceuticals located?

Ligand Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ligand Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ligand Pharmaceuticals from 4/19/2007 amounting to 2.5 USD, you needed to have the stock in your portfolio before the ex-date on 4/3/2007.

When did Ligand Pharmaceuticals pay the last dividend?

The last dividend was paid out on 4/19/2007.

What was the dividend of Ligand Pharmaceuticals in the year 2023?

In the year 2023, Ligand Pharmaceuticals distributed 0 USD as dividends.

In which currency does Ligand Pharmaceuticals pay out the dividend?

The dividends of Ligand Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Ligand Pharmaceuticals

Our stock analysis for Ligand Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ligand Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.